应交易所要求,美/港股行情延时15分钟展示,下载APP即可免费查看实时行情。
关闭
BBIO BridgeBio Pharma, Inc.
休市中 03-14 16:00:00 EDT
32.97
+0.66
+2.04%
盘后
32.97
+0.00
0.00%
16:48 EDT
最高
33.45
最低
32.42
成交量
157.76万
今开
32.59
昨收
32.31
日振幅
3.19%
总市值
62.71亿
流通市值
45.86亿
总股本
1.90亿
成交额
5,192万
换手率
1.13%
流通股本
1.39亿
市净率
--
ROE
--
每股收益
0.00
52周最高
--
52周最低
--
市盈率
--
股息
--
股息收益率
--
ROA
--
分时
五日
日K
周K
月K
数据加载中...
北京优虎网络科技有限公司
资讯
新帖
简况
Bridgebio Pharma, Inc.盘中异动 大幅下跌8.49%
市场透视 · 03-06
Bridgebio Pharma, Inc.盘中异动 大幅下跌8.49%
Bridgebio Pharma, Inc.盘中异动 下午盘急速下跌5.07%报33.13美元
市场透视 · 03-04
Bridgebio Pharma, Inc.盘中异动 下午盘急速下跌5.07%报33.13美元
异动解读 | BridgeBio Pharma宣布再融资发债,股价盘中下跌5.71%
异动解读 · 02-25
异动解读 | BridgeBio Pharma宣布再融资发债,股价盘中下跌5.71%
Bridgebio Pharma, Inc.盘中异动 早盘大幅跳水8.81%
市场透视 · 02-25
Bridgebio Pharma, Inc.盘中异动 早盘大幅跳水8.81%
Bridgebio Pharma, Inc.2024财年实现净利润-5.36亿美元,同比增加16.64%
市场透视 · 02-24
Bridgebio Pharma, Inc.2024财年实现净利润-5.36亿美元,同比增加16.64%
花旗:维持BridgeBio Pharma(BBIO.US)评级,由买入调整至买入评级, 目标价由45.00美元调整至49.00美元。
金融界 · 02-22
花旗:维持BridgeBio Pharma(BBIO.US)评级,由买入调整至买入评级, 目标价由45.00美元调整至49.00美元。
Scotiabank:维持BridgeBio Pharma(BBIO.US)评级,由跑赢大盘调整至跑赢大盘评级, 目标价由49.00美元调整至52.00美元。
金融界 · 02-21
Scotiabank:维持BridgeBio Pharma(BBIO.US)评级,由跑赢大盘调整至跑赢大盘评级, 目标价由49.00美元调整至52.00美元。
BridgeBio Pharma第四季度每股收益$(1.40)未达预期$(1.14),销售额$5.88百万超预期$3.48百万
财报速递 · 02-20
BridgeBio Pharma第四季度每股收益$(1.40)未达预期$(1.14),销售额$5.88百万超预期$3.48百万
Bridgebio Pharma, Inc.盘中异动 早盘股价大涨5.03%
市场透视 · 02-04
Bridgebio Pharma, Inc.盘中异动 早盘股价大涨5.03%
Bridgebio Pharma, Inc.盘中异动 快速下挫5.00%报32.50美元
市场透视 · 02-03
Bridgebio Pharma, Inc.盘中异动 快速下挫5.00%报32.50美元
Bridgebio Pharma, Inc.盘中异动 股价大涨5.09%
市场透视 · 01-22
Bridgebio Pharma, Inc.盘中异动 股价大涨5.09%
Bridgebio Pharma, Inc.盘中异动 急速拉升5.57%
市场透视 · 01-13
Bridgebio Pharma, Inc.盘中异动 急速拉升5.57%
Evercore ISI Group:维持BridgeBio Pharma评级
证券之星 · 2024-12-24
Evercore ISI Group:维持BridgeBio Pharma评级
Evercore ISI Group:维持BridgeBio Pharma(BBIO.US)评级,由优于大市调整至优于大市评级, 目标价由45.00美元调整至50.00美元。
金融界 · 2024-12-24
Evercore ISI Group:维持BridgeBio Pharma(BBIO.US)评级,由优于大市调整至优于大市评级, 目标价由45.00美元调整至50.00美元。
Bridgebio Pharma, Inc.盘中异动 下午盘快速跳水5.04%
市场透视 · 2024-12-13
Bridgebio Pharma, Inc.盘中异动 下午盘快速跳水5.04%
Bridgebio Pharma, Inc.盘中异动 早盘股价大涨5.03%报28.00美元
市场透视 · 2024-12-06
Bridgebio Pharma, Inc.盘中异动 早盘股价大涨5.03%报28.00美元
Bridgebio Pharma, Inc.盘中异动 股价大涨21.90%报28.55美元
市场透视 · 2024-11-25
Bridgebio Pharma, Inc.盘中异动 股价大涨21.90%报28.55美元
Bridgebio Pharma, Inc.2024财年第三财季实现净利润-1.62亿美元,同比增加8.47%
市场透视 · 2024-11-19
Bridgebio Pharma, Inc.2024财年第三财季实现净利润-1.62亿美元,同比增加8.47%
Bridgebio Pharma, Inc.盘中异动 下午盘急速下跌5.10%报22.51美元
市场透视 · 2024-11-19
Bridgebio Pharma, Inc.盘中异动 下午盘急速下跌5.10%报22.51美元
Bridgebio Pharma, Inc.盘中异动 股价大跌5.11%报24.79美元
市场透视 · 2024-11-13
Bridgebio Pharma, Inc.盘中异动 股价大跌5.11%报24.79美元
加载更多
公司概况
公司名称:
BridgeBio Pharma, Inc.
所属市场:
NASDAQ
上市日期:
--
主营业务:
BridgeBio Pharma, Inc.于2019年5月17日在特拉华州成立。该公司是一家处于商业阶段的生物制药公司,旨在发现、创造、测试和提供具有变革性的药物,以治疗具有明确遗传驱动因素的遗传性疾病和癌症患者。
发行价格:
--
{"stockData":{"symbol":"BBIO","market":"US","secType":"STK","nameCN":"BridgeBio Pharma, Inc.","latestPrice":32.97,"timestamp":1741982400000,"preClose":32.31,"halted":0,"volume":1577570,"hourTrading":{"tag":"盘后","latestPrice":32.97,"preClose":32.97,"latestTime":"16:48 EDT","volume":245989,"amount":8110245.83,"timestamp":1741985307994},"delay":0,"floatShares":139092378,"shares":190188626,"eps":-2.879266,"marketStatus":"休市中","change":0.66,"latestTime":"03-14 16:00:00 EDT","open":32.59,"high":33.45,"low":32.42,"amount":51920488.48302,"amplitude":0.031879,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-2.879266,"tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1742198400000},"marketStatusCode":7,"adr":0,"listingDate":1561608000000,"exchange":"NASDAQ","adjPreClose":32.31,"preHourTrading":{"tag":"盘前","latestPrice":32.02,"preClose":32.31,"latestTime":"08:45 EDT","volume":3,"amount":95.34,"timestamp":1741956307862},"postHourTrading":{"tag":"盘后","latestPrice":32.97,"preClose":32.97,"latestTime":"16:48 EDT","volume":245989,"amount":8110245.83,"timestamp":1741985307994},"volumeRatio":0.48180924768787475,"impliedVol":0.6536,"impliedVolPercentile":0.628},"requestUrl":"/m/hq/s/BBIO","defaultTab":"news","newsList":[{"id":"2517655651","title":"Bridgebio Pharma, Inc.盘中异动 大幅下跌8.49%","url":"https://stock-news.laohu8.com/highlight/detail?id=2517655651","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2517655651?lang=zh_cn&edition=full","pubTime":"2025-03-06 22:31","pubTimestamp":1741271481,"startTime":"0","endTime":"0","summary":"北京时间2025年03月06日22时31分,Bridgebio Pharma, Inc.股票出现异动,股价快速下挫8.49%。Bridgebio Pharma, Inc.股票所在的生物技术行业中,整体跌幅为0.63%。其相关个股中,Plus Therapeutics, Inc.、Aspire Biopharma Holdings Inc C/Wts 14/02/2030 、Exicure, Inc.涨幅较大,Plus Therapeutics, Inc.、Aeon Biopharma, Inc.、Allarity Therapeutics, Inc.较为活跃,换手率分别为910.65%、96.25%、44.75%,振幅较大的相关个股有Mbx Biosciences, Inc.、Tiziana Life Sciences Ltd、Astria Therapeutics, Inc.,振幅分别为8.18%、8.09%、7.54%。Bridgebio Pharma, Inc.公司简介:BridgeBio Pharma是一家生物技术公司,专注于发现、开发、测试和提供针对遗传疾病患者的变革性治疗方法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250306223122a2628f81&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250306223122a2628f81&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4588","BK4585","BBIO","BK4139","BK4505"],"gpt_icon":0},{"id":"2516639846","title":"Bridgebio Pharma, Inc.盘中异动 下午盘急速下跌5.07%报33.13美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2516639846","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2516639846?lang=zh_cn&edition=full","pubTime":"2025-03-04 04:21","pubTimestamp":1741033285,"startTime":"0","endTime":"0","summary":"北京时间2025年03月04日04时21分,Bridgebio Pharma, Inc.股票出现波动,股价急速下跌5.07%。Bridgebio Pharma, Inc.股票所在的生物技术行业中,整体涨幅为0.07%。其相关个股中,Bioxcel Therapeutics, Inc.、Abpro Holdings Inc C/Wts 12/11/2029 、Celularity Inc C/Wts 16/07/2026 涨幅较大,Bioxcel Therapeutics, Inc.、Allarity Therapeutics, Inc.、Entero Therapeutics Inc.较为活跃,换手率分别为4602.90%、213.18%、183.34%,振幅较大的相关个股有Bioxcel Therapeutics, Inc.、Radiopharm Theranostics Limited、Entero Therapeutics Inc.,振幅分别为206.20%、119.50%、70.53%。Bridgebio Pharma, Inc.公司简介:BridgeBio Pharma是一家生物技术公司,专注于发现、开发、测试和提供针对遗传疾病患者的变革性治疗方法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250304042127a25da0cb&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250304042127a25da0cb&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4585","BBIO","BK4505","BK4588","BK4139"],"gpt_icon":0},{"id":"1105365958","title":"异动解读 | BridgeBio Pharma宣布再融资发债,股价盘中下跌5.71%","url":"https://stock-news.laohu8.com/highlight/detail?id=1105365958","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1105365958?lang=zh_cn&edition=full","pubTime":"2025-02-25 22:34","pubTimestamp":1740494090,"startTime":"0","endTime":"0","summary":"BridgeBio Pharma(股票代码:BBIO)今日盘中大跌5.71%,引发投资者关注。\n\n公司宣布,将非公开发行5亿美元6年期可转换债券,用于偿还借款和回购股票。此举导致二级市场抛售潮,令股价承压。据报道,部分债券收益将用于从持有人手中回购最多5000万美元的普通股。\n\n近期该公司业绩向好,医疗用品营收增长,分析师给予较高的目标股价评级。公司还期望旗下罕见性心脏病药物持续销售强劲,有望带来新的增长点。不过市场担心再融资计划或因募资压力而冲击盈利表现,加上回购股票导致股本摊薄,短期内股价承压。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"异动解读 | BridgeBio Pharma宣布再融资发债,股价盘中下跌5.71%","news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["BBIO"],"gpt_icon":0},{"id":"2514090324","title":"Bridgebio Pharma, Inc.盘中异动 早盘大幅跳水8.81%","url":"https://stock-news.laohu8.com/highlight/detail?id=2514090324","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2514090324?lang=zh_cn&edition=full","pubTime":"2025-02-25 22:31","pubTimestamp":1740493894,"startTime":"0","endTime":"0","summary":"北京时间2025年02月25日22时31分,Bridgebio Pharma, Inc.股票出现异动,股价大幅下跌8.81%。Bridgebio Pharma, Inc.股票所在的生物技术行业中,整体涨幅为0.36%。其相关个股中,Organovo Holdings, Inc.、Moleculin Biotech, Inc.、Adial Pharmaceuticals, Inc涨幅较大,Gt Biopharma, Inc.、Organovo Holdings, Inc.、Moleculin Biotech, Inc.较为活跃,换手率分别为749.11%、542.73%、463.20%,振幅较大的相关个股有Organovo Holdings, Inc.、Adial Pharmaceuticals, Inc、Maze Therapeutics, Inc.,振幅分别为62.33%、19.20%、8.87%。Bridgebio Pharma, Inc.公司简介:BridgeBio Pharma是一家生物技术公司,专注于发现、开发、测试和提供针对遗传疾病患者的变革性治疗方法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250225223134abdc7dd5&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250225223134abdc7dd5&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","BK4505","BBIO","BK4588","BK4585"],"gpt_icon":0},{"id":"2513569487","title":"Bridgebio Pharma, Inc.2024财年实现净利润-5.36亿美元,同比增加16.64%","url":"https://stock-news.laohu8.com/highlight/detail?id=2513569487","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2513569487?lang=zh_cn&edition=full","pubTime":"2025-02-24 00:00","pubTimestamp":1740326459,"startTime":"0","endTime":"0","summary":"2月24日,Bridgebio Pharma, Inc.公布财报,公告显示公司2024财年净利润为-5.36亿美元,同比增加16.64%;其中营业收入为2.22亿美元,同比增加2287.10%,每股基本收益为-2.88美元。从资产负债表来看,Bridgebio Pharma, Inc.总负债23.77亿美元,其中短期债务4.65百万美元,资产负债比为0.39,流动比率为4.69。机构评级:截至2025年2月24日,当前有14家机构对Bridgebio Pharma, Inc.目标价做出预测,其中目标均价为53.43美元,其中最低目标价为37.00美元,最高目标价为95.00美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250224000125abd9c7d4&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250224000125abd9c7d4&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BBIO"],"gpt_icon":0},{"id":"2513156602","title":"花旗:维持BridgeBio Pharma(BBIO.US)评级,由买入调整至买入评级, 目标价由45.00美元调整至49.00美元。","url":"https://stock-news.laohu8.com/highlight/detail?id=2513156602","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2513156602?lang=zh_cn&edition=full","pubTime":"2025-02-22 02:01","pubTimestamp":1740160873,"startTime":"0","endTime":"0","summary":"花旗:维持BridgeBio Pharma(BBIO.US)评级,由买入调整至买入评级, 目标价由45.00美元调整至49.00美元。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/02/22020148321166.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["BBIO"],"gpt_icon":0},{"id":"2513388292","title":"Scotiabank:维持BridgeBio Pharma(BBIO.US)评级,由跑赢大盘调整至跑赢大盘评级, 目标价由49.00美元调整至52.00美元。","url":"https://stock-news.laohu8.com/highlight/detail?id=2513388292","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2513388292?lang=zh_cn&edition=full","pubTime":"2025-02-21 23:51","pubTimestamp":1740153113,"startTime":"0","endTime":"0","summary":"Scotiabank:维持BridgeBio Pharma(BBIO.US)评级,由跑赢大盘调整至跑赢大盘评级, 目标价由49.00美元调整至52.00美元。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/02/21235148320798.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["BBIO"],"gpt_icon":0},{"id":"1152762211","title":"BridgeBio Pharma第四季度每股收益$(1.40)未达预期$(1.14),销售额$5.88百万超预期$3.48百万","url":"https://stock-news.laohu8.com/highlight/detail?id=1152762211","media":"财报速递","labels":["express"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1152762211?lang=zh_cn&edition=full","pubTime":"2025-02-20 20:39","pubTimestamp":1740055154,"startTime":"0","endTime":"0","summary":"BridgeBio Pharma 报告季度每股亏损$,低于分析师普遍预期的$,差22.81%。公司报告季度销售额$5.88百万,超过分析师普遍预期的$3.48百万,高出69.05%。这是较去年同期销售额$1.75百万增长了237.08%。以上内容来自Benzinga Earnings专栏,原文如下:BridgeBio Pharma reported quarterly losses of $ per share which missed the analyst consensus estimate of $ by 22.81 percent. This is a 45.83 percent decrease over losses of $ per share from the same period last year. The company reported quarterly sales of $5.88 million which beat the analyst consensus estimate of $3.48 million by 69.05 percent.","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"BridgeBio Pharma第四季度每股收益$(1.40)未达预期$(1.14),销售额$5.88百万超预期$3.48百万","news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BBIO"],"gpt_icon":1},{"id":"2508687124","title":"Bridgebio Pharma, Inc.盘中异动 早盘股价大涨5.03%","url":"https://stock-news.laohu8.com/highlight/detail?id=2508687124","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2508687124?lang=zh_cn&edition=full","pubTime":"2025-02-04 23:12","pubTimestamp":1738681973,"startTime":"0","endTime":"0","summary":"北京时间2025年02月04日23时12分,Bridgebio Pharma, Inc.股票出现异动,股价大幅上涨5.03%。Bridgebio Pharma, Inc.股票所在的生物技术行业中,整体涨幅为1.15%。其相关个股中,Azitra Inc、Evaxion Biotech As、Achilles Therapeutics Plc Ads Each Repr 1 Share Spon涨幅较大,Azitra Inc、Evaxion Biotech As、Enveric Biosciences, Inc.较为活跃,换手率分别为1444.89%、862.30%、219.98%,振幅较大的相关个股有Azitra Inc、Lakeshore Biopharma Co Ltd C/Wts 15/03/2028 、Omega Therapeutics, Inc.,振幅分别为62.91%、49.87%、43.21%。Bridgebio Pharma, Inc.公司简介:BridgeBio Pharma是一家生物技术公司,专注于发现、开发、测试和提供针对遗传疾病患者的变革性治疗方法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250204231253a2393157&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250204231253a2393157&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4505","BK4585","BK4139","BBIO","BK4588"],"gpt_icon":0},{"id":"2508144075","title":"Bridgebio Pharma, Inc.盘中异动 快速下挫5.00%报32.50美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2508144075","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2508144075?lang=zh_cn&edition=full","pubTime":"2025-02-03 23:20","pubTimestamp":1738596021,"startTime":"0","endTime":"0","summary":"北京时间2025年02月03日23时20分,Bridgebio Pharma, Inc.股票出现异动,股价大幅下挫5.00%。Bridgebio Pharma, Inc.股票所在的生物技术行业中,整体跌幅为1.17%。其相关个股中,Hcw Biologics Inc.、Gh Research Plc、Invivyd, Inc.涨幅较大,Hcw Biologics Inc.、Briacell Therapeutics Corp.、Cyclerion Therapeutics, Inc.较为活跃,换手率分别为527.95%、408.32%、297.21%,振幅较大的相关个股有Hcw Biologics Inc.、Invivyd, Inc.、Psyence Biomedical Ltd C/Wts 25/01/2029,振幅分别为144.50%、75.23%、50.76%。Bridgebio Pharma, Inc.公司简介:BridgeBio Pharma是一家生物技术公司,专注于发现、开发、测试和提供针对遗传疾病患者的变革性治疗方法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250203232021987976e8&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250203232021987976e8&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4585","BK4588","BK4505","BBIO","BK4139"],"gpt_icon":0},{"id":"2505202628","title":"Bridgebio Pharma, Inc.盘中异动 股价大涨5.09%","url":"https://stock-news.laohu8.com/highlight/detail?id=2505202628","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2505202628?lang=zh_cn&edition=full","pubTime":"2025-01-22 01:55","pubTimestamp":1737482123,"startTime":"0","endTime":"0","summary":"北京时间2025年01月22日01时55分,Bridgebio Pharma, Inc.股票出现异动,股价快速拉升5.09%。Bridgebio Pharma, Inc.股票所在的生物技术行业中,整体涨幅为2.26%。其相关个股中,Camp4 Therapeutics Corporation、Dogwood Therapeutics, Inc.、Cardio Diagnostics Holdings Inc C/Wts To Pur Com涨幅较大,Dogwood Therapeutics, Inc.、Channel Therapeutics Corporation、Dermata Therapeutics, Inc.较为活跃,换手率分别为799.35%、512.22%、189.04%,振幅较大的相关个股有Channel Therapeutics Corporation、Klotho Neurosciences Inc C/Wts 21/06/2029 、Dogwood Therapeutics, Inc.,振幅分别为96.32%、41.33%、38.48%。Bridgebio Pharma, Inc.公司简介:BridgeBio Pharma是一家生物技术公司,专注于发现、开发、测试和提供针对遗传疾病患者的变革性治疗方法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250122015525abb3722a&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250122015525abb3722a&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4588","BK4585","BBIO","BK4139","BK4505"],"gpt_icon":0},{"id":"2503581926","title":"Bridgebio Pharma, Inc.盘中异动 急速拉升5.57%","url":"https://stock-news.laohu8.com/highlight/detail?id=2503581926","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2503581926?lang=zh_cn&edition=full","pubTime":"2025-01-13 23:39","pubTimestamp":1736782772,"startTime":"0","endTime":"0","summary":"北京时间2025年01月13日23时39分,Bridgebio Pharma, Inc.股票出现波动,股价急速上涨5.57%。Bridgebio Pharma, Inc.股票所在的生物技术行业中,整体跌幅为1.01%。其相关个股中,Phio Pharmaceuticals Corp.、Salarius Pharmaceuticals, Inc.、Kairos Pharma, Ltd.涨幅较大,Phio Pharmaceuticals Corp.、Salarius Pharmaceuticals, Inc.、Silexion Therapeutics Corp较为活跃,换手率分别为9586.57%、4881.57%、416.93%,振幅较大的相关个股有Phio Pharmaceuticals Corp.、Salarius Pharmaceuticals, Inc.、Kairos Pharma, Ltd.,振幅分别为318.93%、203.83%、124.54%。Bridgebio Pharma, Inc.公司简介:BridgeBio Pharma是一家生物技术公司,专注于发现、开发、测试和提供针对遗传疾病患者的变革性治疗方法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202501132339329602601a&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202501132339329602601a&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4505","BK4585","BBIO","BK4139","BK4588"],"gpt_icon":0},{"id":"2493999047","title":"Evercore ISI Group:维持BridgeBio Pharma评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2493999047","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2493999047?lang=zh_cn&edition=full","pubTime":"2024-12-24 02:11","pubTimestamp":1734977482,"startTime":"0","endTime":"0","summary":"evercore ISI Group:维持bridgebio pharma(BBIO.US)评级,由优于大市调整至优于大市评级,目标价由45.00美元调整至50.00美元。BridgeBio Pharma(BBIO.US)公司简介:BridgeBio Pharma是一家生物技术公司,专注于发现、开发、测试和提供针对遗传疾病患者的变革性治疗方法。该公司有四个项目处于研发后期管线,专注于孟德尔遗传病、肿瘤学和基因治疗。其中一个关键项目Attruby(acoramidis)是一种口服小分子,旨在稳定四聚体转甲状腺素蛋白,用于治疗转甲状腺素蛋白淀粉样心肌病。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241224021510a205693d&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241224021510a205693d&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BBIO","EVR"],"gpt_icon":0},{"id":"2493886799","title":"Evercore ISI Group:维持BridgeBio Pharma(BBIO.US)评级,由优于大市调整至优于大市评级, 目标价由45.00美元调整至50.00美元。","url":"https://stock-news.laohu8.com/highlight/detail?id=2493886799","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2493886799?lang=zh_cn&edition=full","pubTime":"2024-12-24 02:04","pubTimestamp":1734977069,"startTime":"0","endTime":"0","summary":"Evercore ISI Group:维持BridgeBio Pharma(BBIO.US)评级,由优于大市调整至优于大市评级, 目标价由45.00美元调整至50.00美元。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2024/12/24020446729393.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["BBIO","EVR"],"gpt_icon":0},{"id":"2491706330","title":"Bridgebio Pharma, Inc.盘中异动 下午盘快速跳水5.04%","url":"https://stock-news.laohu8.com/highlight/detail?id=2491706330","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2491706330?lang=zh_cn&edition=full","pubTime":"2024-12-13 02:25","pubTimestamp":1734027900,"startTime":"0","endTime":"0","summary":"北京时间2024年12月13日02时25分,Bridgebio Pharma, Inc.股票出现波动,股价大幅跳水5.04%。Bridgebio Pharma, Inc.股票所在的生物技术行业中,整体跌幅为1.09%。其相关个股中,Trevi Therapeutics, Inc.、Palisade Bio, Inc.、Cero Therapeutics Holdings Inc C/Wts 13/02/2029 涨幅较大,Palisade Bio, Inc.、Aptevo Therapeutics Inc.、Conduit Pharmaceuticals Inc.较为活跃,换手率分别为3924.05%、1067.88%、89.78%,振幅较大的相关个股有Neurosense Therapeutics Ltd C/Wts 10/11/2026 、Palisade Bio, Inc.、Aptevo Therapeutics Inc.,振幅分别为129.16%、99.29%、95.90%。Bridgebio Pharma, Inc.公司简介:BridgeBio Pharma是一家生物技术公司,专注于发现、开发、测试和提供针对遗传疾病患者的变革性治疗方法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241213022500a1e9b887&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241213022500a1e9b887&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4505","BK4585","BBIO","BK4139","BK4588"],"gpt_icon":0},{"id":"2489285237","title":"Bridgebio Pharma, Inc.盘中异动 早盘股价大涨5.03%报28.00美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2489285237","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2489285237?lang=zh_cn&edition=full","pubTime":"2024-12-06 23:57","pubTimestamp":1733500667,"startTime":"0","endTime":"0","summary":"北京时间2024年12月06日23时57分,Bridgebio Pharma, Inc.股票出现异动,股价大幅拉升5.03%。截至发稿,该股报28.00美元/股,成交量27.9448万股,换手率0.15%,振幅5.36%。Bridgebio Pharma, Inc.股票所在的生物技术行业中,整体涨幅为0.68%。Bridgebio Pharma, Inc.公司简介:BridgeBio Pharma是一家生物技术公司,专注于发现、开发、测试和提供针对遗传疾病患者的变革性治疗方法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241206235747ab630171&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241206235747ab630171&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BBIO","BK4585","BK4588","BK4505","BK4139"],"gpt_icon":0},{"id":"2486503315","title":"Bridgebio Pharma, Inc.盘中异动 股价大涨21.90%报28.55美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2486503315","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2486503315?lang=zh_cn&edition=full","pubTime":"2024-11-25 22:31","pubTimestamp":1732545096,"startTime":"0","endTime":"0","summary":"北京时间2024年11月25日22时31分,Bridgebio Pharma, Inc.股票出现波动,股价急速拉升21.90%。Bridgebio Pharma, Inc.股票所在的生物技术行业中,整体涨幅为0.92%。其相关个股中,Scholar Rock Holding Corporation、Citius Pharmaceuticals, Inc.、Bridgebio Pharma, Inc.涨幅较大,Cognition Therapeutics, Inc.、木薯科学、Citius Pharmaceuticals, Inc.较为活跃,换手率分别为85.54%、52.88%、33.80%,振幅较大的相关个股有Werewolf Therapeutics, Inc.、Kodiak Sciences Inc、Celcuity Inc.,振幅分别为103.16%、102.58%、102.58%。Bridgebio Pharma, Inc.公司简介:BridgeBio Pharma Inc 参与确定用于治疗孟德尔病患者的先进变革性药物,以及具有明确基因驱动因素的癌症。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241125223136a2548bdb&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241125223136a2548bdb&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4505","BK4139","BBIO","BK4585","BK4588"],"gpt_icon":0},{"id":"2484891658","title":"Bridgebio Pharma, Inc.2024财年第三财季实现净利润-1.62亿美元,同比增加8.47%","url":"https://stock-news.laohu8.com/highlight/detail?id=2484891658","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2484891658?lang=zh_cn&edition=full","pubTime":"2024-11-19 18:00","pubTimestamp":1732010416,"startTime":"0","endTime":"0","summary":"11月19日,Bridgebio Pharma, Inc.公布财报,公告显示公司2024财年第三财季净利润为-1.62亿美元,同比增加8.47%;其中营业收入为2.73百万美元,同比减少33.25%,每股基本收益为-0.86美元。从资产负债表来看,Bridgebio Pharma, Inc.总负债18.83亿美元,其中短期债务4.60百万美元,资产负债比为0.36,流动比率为3.21。机构评级:截至2024年11月19日,当前有14家机构对Bridgebio Pharma, Inc.目标价做出预测,其中目标均价为47.93美元,其中最低目标价为37.00美元,最高目标价为70.00美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241119180025abcede9d&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241119180025abcede9d&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BBIO"],"gpt_icon":0},{"id":"2484983799","title":"Bridgebio Pharma, Inc.盘中异动 下午盘急速下跌5.10%报22.51美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2484983799","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2484983799?lang=zh_cn&edition=full","pubTime":"2024-11-19 04:16","pubTimestamp":1731960993,"startTime":"0","endTime":"0","summary":"北京时间2024年11月19日04时16分,Bridgebio Pharma, Inc.股票出现异动,股价大幅跳水5.10%。Bridgebio Pharma, Inc.股票所在的生物技术行业中,整体涨幅为0.09%。其相关个股中,Hcw Biologics Inc.、冠科美博、Apollomics Inc C/Wts 01/04/2028 涨幅较大,冠科美博、Hcw Biologics Inc.、Tharimmune, Inc.较为活跃,换手率分别为1485.81%、1316.96%、581.36%,振幅较大的相关个股有Hcw Biologics Inc.、冠科美博、Apollomics Inc C/Wts 01/04/2028 ,振幅分别为563.48%、221.58%、193.44%。Bridgebio Pharma, Inc.公司简介:BridgeBio Pharma Inc 参与确定用于治疗孟德尔病患者的先进变革性药物,以及具有明确基因驱动因素的癌症。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024111904163398e4355a&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024111904163398e4355a&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BBIO","BK4585","BK4588","BK4139","BK4505"],"gpt_icon":0},{"id":"2483031434","title":"Bridgebio Pharma, Inc.盘中异动 股价大跌5.11%报24.79美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2483031434","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2483031434?lang=zh_cn&edition=full","pubTime":"2024-11-13 01:34","pubTimestamp":1731432897,"startTime":"0","endTime":"0","summary":"北京时间2024年11月13日01时34分,Bridgebio Pharma, Inc.股票出现波动,股价急速下挫5.11%。Bridgebio Pharma, Inc.股票所在的生物技术行业中,整体跌幅为0.67%。Bridgebio Pharma, Inc.公司简介:BridgeBio Pharma Inc 参与确定用于治疗孟德尔病患者的先进变革性药物,以及具有明确基因驱动因素的癌症。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241113013457971a616e&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241113013457971a616e&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","BK4588","BK4585","BK4505","BBIO"],"gpt_icon":0}],"profile":{"websiteUrl":"http://bridgebio.com;investor.bridgebio.com","stockEarnings":[{"period":"1week","weight":0.0443},{"period":"1month","weight":0.0319},{"period":"3month","weight":0.1993},{"period":"6month","weight":0.2594},{"period":"1year","weight":0.2055},{"period":"ytd","weight":0.2015}],"compareEarnings":[{"period":"1week","weight":-0.0228},{"period":"1month","weight":-0.0672},{"period":"3month","weight":-0.0685},{"period":"6month","weight":0.0014},{"period":"1year","weight":0.0929},{"period":"ytd","weight":-0.0397}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"BridgeBio Pharma, Inc.于2019年5月17日在特拉华州成立。该公司是一家处于商业阶段的生物制药公司,旨在发现、创造、测试和提供具有变革性的药物,以治疗具有明确遗传驱动因素的遗传性疾病和癌症患者。","yearOnYearQuotes":[{"month":1,"riseRate":0.333333,"avgChangeRate":-0.052015},{"month":2,"riseRate":0.5,"avgChangeRate":0.034422},{"month":3,"riseRate":0.333333,"avgChangeRate":0.064072},{"month":4,"riseRate":0.2,"avgChangeRate":-0.108991},{"month":5,"riseRate":0.4,"avgChangeRate":-0.018168},{"month":6,"riseRate":0.8,"avgChangeRate":0.125791},{"month":7,"riseRate":0.5,"avgChangeRate":0.140277},{"month":8,"riseRate":0.666667,"avgChangeRate":0.029525},{"month":9,"riseRate":0.166667,"avgChangeRate":-0.060206},{"month":10,"riseRate":0.666667,"avgChangeRate":0.014306},{"month":11,"riseRate":0.666667,"avgChangeRate":0.094984},{"month":12,"riseRate":0.666667,"avgChangeRate":0.044694}],"exchange":"NASDAQ","name":"BridgeBio Pharma, Inc.","nameEN":"BridgeBio Pharma, Inc."},"APP":{"userAgent":"CCBot/2.0 (https://commoncrawl.org/faq/)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.31.7","shortVersion":"4.31.7","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"BridgeBio Pharma, Inc.(BBIO)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供BridgeBio Pharma, Inc.(BBIO)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"BridgeBio Pharma, Inc.,BBIO,BridgeBio Pharma, Inc.股票,BridgeBio Pharma, Inc.股票老虎,BridgeBio Pharma, Inc.股票老虎国际,BridgeBio Pharma, Inc.行情,BridgeBio Pharma, Inc.股票行情,BridgeBio Pharma, Inc.股价,BridgeBio Pharma, Inc.股市,BridgeBio Pharma, Inc.股票价格,BridgeBio Pharma, Inc.股票交易,BridgeBio Pharma, Inc.股票购买,BridgeBio Pharma, Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"BridgeBio Pharma, Inc.(BBIO)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供BridgeBio Pharma, Inc.(BBIO)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}